ClinicalTrials.gg
RecruitingNCT05757310Updated Jan 5, 2026

A Reduced-Intensity Conditioning Regimen (Cyclophosphamide, Pentostatin, Anti-thymocyte Globulin) Followed by Haploidentical Hematopoietic Stem Cell Transplant for the Treatment of Patients With Refractory or Recurrent Severe Aplastic Anemia

A Phase 1 interventional study of Anti-Thymocyte Globulin and Biospecimen Collection in Recurrent Severe Aplastic Anemia and Refractory Severe Aplastic Anemia, sponsored by City of Hope Medical Center. Recruiting at 1 site in United States. Open to participants aged Up to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-05.

Sponsored by City of Hope Medical Center · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
Up to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing Antilymphocyte Serum in Anemia, Aplastic — 3 open to participants now, 3 under way, none of them phase 3. Antilymphocyte Serum · Anemia, Aplastic.

Planned enrollment
20th of 20
6 · median 38
Started
2024
the only one that year
Phase 1
Only one
of the 20
Registered
19th of 20
by date
Lead sponsor
1 of 20
City of Hope Medical Center

Among the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, this one is the 20th largest by planned enrollment, is the only one that started in 2024, is the only one in phase 1, and was the 19th registered.

Anemia, Aplastic

373 studies on the registry are indexed under Anemia, Aplastic; 98 are open to participants now.

Browse Anemia, Aplastic studies →

Open to participants now

3 of the 20 studies testing Antilymphocyte Serum in Anemia, Aplastic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About Antilymphocyte Serum

Antilymphocyte Serum: first FDA approval 1996 (Atgam). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Anemia, Aplastic studies recruiting now, 20 (35%) set no upper age limit and 29 (51%) stop at 75 or younger; 37 take children under 18; 5 take healthy volunteers.

This study: Up to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing Antilymphocyte Serum in Anemia, Aplastic, or all of them as a file.
02

Study summary

This phase I trial evaluates the safety and feasibility of using a reduced-intensity regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin prior to a CD4+ T-cell depleted haploidentical hematopoietic cell transplant (haploHCT) for the treatment of patients with severe aplastic anemia that does not respond to treatment (refractory) or that has come back (recurrent). Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid. It may also lower the body's immune response. Pentostatin blocks a protein needed for cell growth. Anti-thymocyte globulin is an immunosuppressive drug can destroy immune cells known as T-cells. HaploHCT transfers blood-forming stem cells from a healthy partially-matched donor to a patient. Administering a regimen of cyclophosphamide, pentostatin, and anti-thymocyte globulin before haploHCT may help make room for the new, healthy cells and may reduce the risk of graft versus host disease.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine if the infusion of CD4+ T-cell-depleted hematopoietic cells from a haploidentical donor, following a non-myeloablative/ reduced-intensity preparative regimen is safe in patients with severe aplastic anemia (SAA).

II. To determine the feasibility of producing an infusion ready CD4+ T-cell-depleted hematopoietic product, as assessed by:

IIa. Ability to meet the minimum required CD34+ cell dose, and; IIb. Ability to meet the CD4+ T-cell depletion product release requirements.

SECONDARY OBJECTIVES:

I. To evaluate toxicities including type, frequency, severity, attribution, time course, and duration. (Safety/tolerability) II. To summarize and evaluate hematologic (neutrophil and platelet) recovery, including marrow failure. (Safety/tolerability) III. To estimate the incidence of infection and infectious disease related complications at 100 days. (Safety/tolerability) IV. To estimate the incidence of SAA related complications. (Safety/tolerability) V. To estimate the cumulative incidence of non-relapse mortality at 100-days, 1-year and 2-years post hematopoietic stem-cell transplantation (HCT). (Safety/tolerability) VI. To estimate the cumulative incidence of acute graft versus host disease (GvHD) (grades: II-IV, III-IV) at 100-days and chronic GvHD (grades: any, moderate-severe) at 6-months, 1-year and 2-years post HCT. (Safety/tolerability) VII. To estimate the overall survival probability at 100-days, 1-year and 2-years post HCT. (Survival/relapse) VIII. To estimate the disease-free survival probability at 100-days, 1-year and 2-years post HCT. (Survival/relapse) IX. To estimate the event-free survival probability at 100-days, 1-year and 2-years post HCT. (Survival/relapse) X. To estimate the cumulative incidence of disease relapse at 100-days, 1-year and 2-years post HCT. (Survival/relapse) XI. To describe response as categorized by graft failure, persistent post-immunosuppressant (IS) mixed chimerism, persistent IS-dependent mixed chimerism, complete chimerism. (Chimerism) XII. To summarize/characterize patient chimerism (percent of donor total nucleated and donor lineage specific cells) over time. (Kinetics)

EXPLORATORY OBJECTIVES:

I. To describe the ratio of donor to recipient de novo thymic T cells over the course of 2 years within the peripheral blood compartment.

II. To describe the ratio of donor to recipient regulatory T cells and regulatory B cells over the course of 2 years within the peripheral blood and bone marrow compartments.

III. To describe the tolerance status of donor and host-type T cells over the course of 2 years within the peripheral blood compartment.

IV. To describe the T-cell repertoire of donor- and host-type T cells over the course of 2 years within the peripheral blood compartment.

V. To describe the bone marrow niche and peripheral blood cytokine profile over time.

VI. To describe bone marrow progenitor chimerism over time.

OUTLINE:

Patients receive cyclophosphamide orally (PO) and intravenously (IV), pentostatin IV, anti-thymocyte globulin IV and undergo CD4+ T-cell depleted haploHCT on study. Patients also undergo bone marrow aspirate, bone marrow biopsy, and collection of blood samples at screening and follow-up.

03

Conditions studied

  • Recurrent Severe Aplastic Anemia
  • Refractory Severe Aplastic Anemia

Browse trials for

04

Who can participate

Ages eligible
Up to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • RECIPIENT: Documented of the participant.
  • RECIPIENT: Age: >= 40 years but =\< 75 years of age at time of enrollment.
  • RECIPIENT: Failed at least one trial of therapy (IST) by being (persistence of severe cytopenia and fulfillment of SAA disease criteria at least 3 months after initial IST) or having relapsed (initial improvement of cytopenia after IST but then a later return to fulfillment of SAA disease criteria when IST is decreased or ceased). IST could have included anti-thymocyte globulin (ATG) based regimens, calcineuPririn inhibitors and/or other higher dose therapy directed at the treatment of primary SAA.
  • RECIPIENT: performance score >= 60%.
  • RECIPIENT: Confirmed diagnosis of severe aplastic anemia as:

    • Bone marrow cellularity \< 25% or marrow cellularity \< 50% but with \< 30% residual hematopoietic cells;
    • Two out of three of the following (in peripheral blood):

      • Neutrophils \< 0.5 x 10\^9/L;
      • \< 20 x 10\^9/L;
      • Reticulocyte count \< 20 x 10\^9/L (\< 60 x 10\^9/L using an automated analysis).
  • RECIPIENT: No suitable fully matched related sibling donor (6/6 match for human leukocyte antigen [HLA]-A and B at intermediate or high resolution and DRbetaA1 at high resolution using deoxyribonucleic acid [DNA]-based typing) available.
  • RECIPIENT: Available relative of the patient who is a haploidentical match, including biological parents, siblings or half siblings, children, uncles/aunts, first cousins, etc. Eligible haploidentical donors will have 2-4 mismatches if HLA-A, -B, -C, and -DRB1 typing is used; 2-5 mismatches if HLA-A, -B, -C, -DRB1, and -DQB1 typing is used; and 2-6 mismatches if HLA-A, -B, -C, -DRB1, -DQB1, and -DPB1 typing is used. A unidirectional mismatch in either the graft versus host or host versus graft direction is considered a mismatch. The donor and recipient must demonstrate that they are a full haplotype match by being identical at a minimum of one allele (at high resolution DNA-based typing) at the following genetic loci: HLA-A, -B, -C, and DRB1 if 8 allele typing is used; HLA-A, -B, -C, -DRB1, and -DQB1 if 10 allele typing is used; and HLA-A, -B, -C, -DRB1-, DQB1, and -DPB1 is 12 allele typing is used by the local center.
  • RECIPIENT: Patient and/or legal guardian must sign informed consent for the hematopoietic stem cell transplantation ().
  • RECIPIENT: The haplo donor and/or legal guardian must be able to sign informed consent documents.
  • RECIPIENT: The potential haplo donor must be willing and able to donate bone marrow.
  • RECIPIENT: The weight of the haplo donor must be >= 20 kg.
  • RECIPIENT: Total \< 3.0 x the (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit)
  • RECIPIENT: (AST) =\< 5.0 x ULN.
  • RECIPIENT: Alanine transaminase (ALT) =\< 5.0 x ULN.
  • RECIPIENT:

    • For patients >= 13.0 years of age at the time of enrollment: of >= 50 mL/min per 24 hour urine test or the Cockcroft-Gault formula.
    • For patients \< 13 years of age at enrollment: (GFR) estimated by the updated Schwartz formula > 90 mL/min/1.73 m\^2. If the estimated GFR is \< 90 mL/min/1.73m\^2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 50mL/min/1.73m\^2.
  • RECIPIENT: Women of (WOCBP): negative urine or serum pregnancy test If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • RECIPIENT: Echocardiogram (ECHO) or multigated acquisition (): Left ventricular ejection fraction (LVEF) at rest >= 40%. For patients aged \< 13 years, shortening fraction (SF) >= 26% by echocardiogram or MUGA may be substituted for LVEF.
  • RECIPIENT:

    • For patients > 13.0 years of age: Diffusing capacity of the lung for carbon monoxide (DLCO) (corrected/adjusted for ) > 40% and (FEV1) > 50% predicted (without administration of bronchodilator) and forced vital capacity (FVC) > 50% predicted.
    • For patients \< 13.0 years of age unable to perform pulmonary function tests (PFTs) due to age or developmental ability: (1) no evidence of dyspnea at rest and (2) no need for supplemental oxygen and (3) oxygen (O2) saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care [e.g., Utah, 4,200 feet above sea level, does not give supplemental oxygen unless below 90%]).
  • RECIPIENT: Seronegative for (HIV) antigen and antibody (Ag/Ab) combo, virus (HCV), active virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR])

    • If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed.
  • RECIPIENT: Antibodies to donor red blood cell antigens including ABO and rhesus (Rh) meets institutional titer requirements.
  • RECIPIENT: WOCBP or sexually active male: Agreement to use adequate prior to study entry and 6 months post-CD4+ T-cell-depleted-HaploHCT.
  • DONOR: Documented protocol-specific City of Hope (COH) informed consent per local, state and federal guidelines
  • DONOR: Documented general institutional informed consent per local, state and federal guidelines.
  • DONOR: Age: younger than 60 years.
  • DONOR: Haplo donor selection is based on HLA typing and relationship to recipient.
  • DONOR: When more than one donor is available, the donor with the lowest number of HLA allele mismatches will be chosen unless there is HLA cross-match incompatibility or a medical reason to select otherwise. In cases where there is more than one donor with the least degree of mismatch, donors will be selected based on the most favorable combination of HLA compatibility in cross-match testing and ABO compatibility. Prioritization is given to the lowest number of mismatches in the host-versus-graft (HVG) direction to minimize the risk of graft failure.
  • DONOR: If there is more than one donor with the least amount of host-versus-graft (HVG) allele mismatches, the suggested prioritization in order of importance includes ABO compatibility, cytomegalovirus (CMV) status (use a sero-negative donor for a sero-negative recipient or use a sero-positive donor for a sero-positive recipient), younger age and lighter weight (this rule applies down to the age of 18, however, children may also be used as donors if appropriate), and sex of the donor (if all else is equal, males are preferred over nulliparous females over multiparous females).
  • DONOR: Infectious disease screening performed within 30 days prior to stem cell collection and per federal guidelines and is:

    • Seronegative for HIV Ag, HIV 1+2 Ab, human T-lymphotropic virus (HTLV) I/II Ab, hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (HBcAb) (immunoglobulin M [IgM] and immunoglobulin G [IgG]), HCV Ab;
    • Negative RPR for syphilis.
  • DONOR: WOCBP: Urine pregnancy testing performed within 7 days prior to stem cell mobilization
  • DONOR: Is approved and completed evaluation per institutional guidelines.

Exclusion criteria

Exclusion Criteria:

  • RECIPIENT: Inherited and acquired (non-aplastic anemia) bone marrow failure syndromes such as Fanconi anemia must be ruled out according to center standards.
  • RECIPIENT: Clonal cytogenetic abnormalities consistent with pre-myelodysplastic syndrome (pre-MDS) or MDS on marrow examination (e.g. Monosomy 7).
  • RECIPIENT: Any somatic mutations (including TERT, TERC, DKC1, NOP10) other than PIG-A (PNH) or BCOR mutation.
  • RECIPIENT: Diagnosis of myelodysplastic syndrome (MDS).
  • RECIPIENT: Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a positive cross-match test of any titer by complement-dependent cytotoxicity or flow cytometric testing or the presence of anti-donor HLA antibody to the high expression loci HLA-A, B, C, DRB1, or DPB1 with mean fluorescence intensity [MFI] > 1000 by solid phase immunoassay).
  • RECIPIENT: Prior stem cell transplant.
  • RECIPIENT: Prior solid organ transplant.
  • RECIPIENT: Known life-threatening reaction (i.e., anaphylaxis) to Thymoglobulin (registered trademark) that would prohibit use for the patient as this study requires use of the Thymoglobulin (registered trademark) preparation of ATG.
  • RECIPIENT: Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.
  • RECIPIENT: Seropositive for the (HIV).
  • RECIPIENT: Active or C determined by a detectable viral load of HBV or .
  • RECIPIENT: Female patients who are pregnant (per institutional practice) or breast-feeding.
  • RECIPIENT: Prior except resected basal cell carcinoma or treated cervical carcinoma in situ. Cancer treated with curative intent > 5 years previously will be allowed. Cancer treated with curative intent =\< 5 years previously will not be allowed unless approved by the protocol chairs and/or protocol officer.
  • RECIPIENT: Alemtuzumab or ATG within 2 weeks of enrollment.
  • RECIPIENT: Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
  • RECIPIENT: Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics).
  • DONOR: Has undergone any transplantation (i.e. organ, stem cell, bone marrow, blood).
  • DONOR: Receiving any agents, or concurrent biological, chemotherapy, or radiation therapy.
  • DONOR: Active infection.
  • DONOR: Medical or physical reason which makes the donor unlikely to tolerate or cooperate with growth factor therapy and leukapheresis.
  • DONOR: Factors which place the donor at increased risk for complications from leukapheresis or granulocyte colony-stimulating factor (G-CSF) therapy.
  • DONOR: : pregnant or =\< 6 months breastfeeding.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    Treatment (conditioning, haploHCT)

    Patients receive cyclophosphamide PO and IV, pentostatin IV, anti-thymocyte globulin IV and undergo CD4+ T-cell depleted haploHCT on study. Patients also undergo bone marrow aspirate, bone marrow biopsy, and collection of blood samples at screening and follow-up.

    Biological: Anti-Thymocyte Globulin · Procedure: Biospecimen Collection · Procedure: Bone Marrow Aspirate · Procedure: Bone Marrow Biopsy · Drug: Cyclophosphamide · Procedure: Haploidentical Hematopoietic Cell Transplantation · Drug: Pentostatin · Other: Questionnaire Administration

Interventions

  • BiologicalAntilymphocyte SerumStudies of Antilymphocyte SerumAntilymphocyte Serum pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given IV

    Also known as: Antithymocyte Globulin, Antithymocyte Serum, ATG, ATS

  • ProcedureBiospecimen Collection

    Undergo blood sample collection

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureBone Marrow Aspirate

    Undergo bone marrow aspirate

    Also known as: Human Bone Marrow Aspirate

  • ProcedureBone Marrow Biopsy

    Undergo bone marrow biopsy

    Also known as: Biopsy of Bone Marrow, Biopsy, Bone Marrow

  • Given PO and IV

    Also known as: (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719

  • ProcedureHaploidentical Hematopoietic Cell Transplantation

    Undergo CD4+ T-cell depleted haploHCT

    Also known as: Haploidentical Stem Cell Transplantation, HLA-Haploidentical Hematopoietic Cell Transplantation, Stem Cell Transplantation, Haploidentical

  • Given IV

    Also known as: (R)-3-(2-Deoxy-.beta.-D-erythro-pentofuranosyl)-3,6,7, 8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol, 2'-Deoxycoformycin, CI-825, Co-Vidarabine, Covidarabine, DCF, Deoxycoformycin, Nipent, PD-81565, Pentostatine

  • OtherQuestionnaire Administration

    Ancillary studies

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events

    Toxicity will be graded according to the National Cancer Institute's-Common Terminology Criteria for Adverse Events version 5.0. Graft versus host disease (GVHD) specific toxicities will be defined per 1994 Keystone Consensus Criteria. Observed toxicities will be summarized in terms of type (organ affected or laboratory determination), severity, time of onset, duration, probable association with the study regimen and reversibility or outcome. This will include infectious disease related complications and autoimmune disease related complications. Cumulative incidence curves will be used for time to event variables with competing risks events such as acute GVHD or chronic GVHD. Point estimates and 90% confidence intervals will be used.

    Time frame: From day -22 to day +100 or occurrence of unacceptable toxicity, whichever occurs first

  2. Ability to meet CD4+ T-cell depleted product release requirements (feasibility)

    The feasibility of producing an infusion ready CD4+ T-cell-depleted hematopoietic product will be assessed by the ability to meet product release requirements. Product release requirements include the following: (1) CD34+ cells: Post-processing CD34+ cell target of 7.5-13.0 x 106 cells/kg of recipient body weight; (2) CD4+ T-cell depletion: \>= 97% of CD4+ T-cells in the the hematopoietic cell product for manufacturing; (3) Sterility (e.g. endotoxin and gram staining). Descriptive statistics will be used to characterize feasibility.

    Time frame: Up to 3 years

  3. Ability to meet minimum required cell dose (feasibility)

    The feasibility of producing an infusion ready CD4+ T-cell-depleted hematopoietic product will be assessed by the ability to meet minimum required cell doses. This outcome will be evaluated using the following: (1) CD34+ collected (per day of apheresis); (2) CD34+ recovery: % CD34+ cells recovered from the CD34+ cell number in the product being manufactured (pre-CD4+ T cell depletion); (3) Cell dose: pooled and back up product; (4) Cell dose adequate given recipient's body weight plus the required pre-processed back-up set aside (yes/no); (5) Number (median, range) of apheresis; (6) % CD4+ T-cell depletion; (7) reason for not meeting product release requirements. Descriptive statistics will be used to characterize feasibility.

    Time frame: Up to 3 years

Secondary outcomes

  1. Incidence of adverse events of grade 3 or higher

    Time frame: Up to 3 years

  2. Incidence of infection

    Microbiologically documented infections will be reported by site of disease, date of onset, severity and resolution, if any.

    Time frame: Up to 3 years

  3. Time to neutrophil recovery

    Time frame: From the date of CD4+ T-cell-depleted product infusion to the first of three consecutive days of absolute neutrophil count (ANC) >= 500/mm^3 and ANC >= 1000/mm^3, assessed up to 3 years

  4. Time to platelet recovery

    Time frame: Time to the first day of the first of three consecutive laboratory values when the platelet count is >= 20,000/mm^3 and 100,000/mm^3 without a platelet transfusion in the previous seven, assessed up to 3 years

  5. Marrow failure

    Defined as primary graft failure: failure to achieve a sustained neutrophil count of \>= 500/ mm\^3 in the absence of disease relapse by 28 days or secondary graft failure: a decline in the neutrophil count to less than 500/ mm\^3 after initial engraftment, which was unrelated to infection, medications, or disease relapse.

    Time frame: Up to 28 days post transplant for primary graft failure or after initial engraftment for secondary graft failure, assessed up to 3 years

  6. Cumulative incidence of non-relapse mortality (NRM)

    NRM is defined as death occurring in a patient from causes other than disease relapse; relapse is a competing event. Cumulative incidence curves will be used for time to event variables with competing risks events. Point estimates and 90% confidence intervals will be used.

    Time frame: From enrollment until non-disease related death or last follow up and from date of CD4+ T-cell-depleted product infusion, assessed up to 3 years

  7. Cumulative incidence of acute GvHD (II-IV and III-IV)

    Acute GvHD is graded according to the Keystone Consensus Criteria. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves; death is a competing event. Cumulative incidence curves will be used for time to event variables with competing risks events. Point estimates and 90% confidence intervals will be used.

    Time frame: From day 0 through day +100 post-transplant

  8. Cumulative incidence of chronic GvHD (any and moderate-severe)

    Chronic GvHD is graded according to the 2014 NIH Consensus Criteria. The first day of chronic GvHD onset at a certain grade will be used to calculate cumulative incidence curves; disease recurrence or death is a competing event. Cumulative incidence curves will be used for time to event variables with competing risks events. Point estimates and 90% confidence intervals will be used.

    Time frame: From day +100 to +2 years post-transplant

  9. Overall survival

    Patients are considered a failure for this endpoint if they die, regardless of cause of death. Overall survival will be censored at last follow-up if patients are known to be alive. Kaplan-Meier curves will be used for time to event variables.

    Time frame: Time from enrollment to death, assessed up to 3 years

  10. Cumulative incidence of relapse

    Disease relapse is defined as a decline in the neutrophil count to less than 500/ mm\^3 after initial engraftment, which was unrelated to infection, medications, or other causes. Death without disease recurrence will be a competing risk event. Time to disease recurrence will be censored at the last disease assessment of patients remain alive and free of disease recurrence.

    Time frame: Time from enrollment/infusion of depleted hematopoietic product to first observation of disease relapse, assessed up to 3 years

  11. Disease-free survival (DFS)

    Patients are considered a failure for this endpoint if they relapse or die, regardless of cause of death. DFS will be censored at last follow-up if patients are alive and free of disease. Kaplan-Meier curves will be used for time to event variables.

    Time frame: Time from enrollment/ infusion of CD4+ T-cell-depleted hematopoietic product to relapse, therapy for hemoglobinopathy, death from any cause, assessed up to 3 years

  12. Event-free survival (EFS)

    EFS will be censored at last follow-up if patients are free of any above-mentioned events. Kaplan-Meier curves will be used for time to event variables.

    Time frame: Time from enrollment/infusion of CD4+ T-cell product to any of the following events (whichever occurs first): therapy for hemoglobinopathy, primary/secondary graft failure, acute GvHD, chronic GvHD, death from any cause, assessed up to 3 years

  13. Chimerism

    Persistent IS-dependent mixed chimerism: Between 10% and 94% donor chimerism at two years post-transplant and on IS. Complete chimerism: \>94% donor chimerism at two years post-transplant. Primary donor graft failure: Defined as \< 10 % donor chimerism by day +30 post-transplant.. Secondary donor graft failure: Defined as \< 10 % donor chimerism beyond day +30 in patients with prior documentation of \>= 10% donor cells by day +30. Failure is based on two separate measurements obtained at least 2 weeks apart. Line charts or scatterplots will be used for changes of endpoints over time such as chimerism.

    Time frame: Up to 2 years

  14. Kinetics

    Will evaluate T-cells: CD3, CD4, CD8, B-cells: CD19, natural killer cells: CD56, monocytes: CD14, granulocytes: CD15, total nucleated cells. Line charts or scatterplots will be used for changes of endpoints over time.

    Time frame: At 7, 15, 30, 60, 100, 180 days and 1, 1.5, and 2 years post-transplant

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2023
First posted
Mar 7, 2023
StartActual
Nov 15, 2024
Primary completionEst.
Jun 18, 2027
CompletionEst.
Jun 18, 2027
Last update
Jan 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05757310
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Nov 15, 2024
Primary completion
Jun 18, 2027 (estimated)
Completion
Jun 18, 2027 (estimated)
Last update
Jan 5, 2026

Study contacts

Ryotaro Nakamura
principal investigator · City of Hope Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Antilymphocyte Serum · Cyclophosphamide · Pentostatin

Start the discussion